{"id":"high-dose-ferric-derisomaltose","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL4298187","moleculeType":"Oligosaccharide"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ferric derisomaltose is an iron(III) carbohydrate complex designed for intravenous administration in iron deficiency anemia. The derisomaltose ligand stabilizes the iron core, allowing controlled release and absorption of iron in the body. This bypasses oral absorption limitations and enables rapid repletion of iron stores and hemoglobin production.","oneSentence":"High-dose ferric derisomaltose delivers iron directly to iron-deficient patients via a stable iron-carbohydrate complex that is absorbed and utilized for hemoglobin synthesis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:47:41.051Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Iron deficiency anemia"}]},"trialDetails":[{"nctId":"NCT06884280","phase":"PHASE3","title":"Comparing High and Low Dose Iron Treatments for People on Peritoneal Dialysis: The PALaDIN Study","status":"RECRUITING","sponsor":"Hull University Teaching Hospitals NHS Trust","startDate":"2025-11-13","conditions":"Peritoneal Dialysis, Anaemia, Iron Deficiency, Anaemia","enrollment":30},{"nctId":"NCT06427343","phase":"PHASE4","title":"The Effects of Low-Dose Versus High-Dose Intravenous IRON Therapy With Ferric DerisomaltOSE in Patients With Chronic Heart Failure and Iron Deficiency","status":"RECRUITING","sponsor":"China-Japan Friendship Hospital","startDate":"2023-10-01","conditions":"Heart Failure, Iron Deficiency","enrollment":114},{"nctId":"NCT04608539","phase":"PHASE4","title":"A Clinical Trial Assessing the Efficacy of Intravenous Iron for the Treatment of Anemia Following Cardiac Surgery","status":"COMPLETED","sponsor":"Michael Kremke","startDate":"2021-05-21","conditions":"Anemia Postoperative","enrollment":110},{"nctId":"NCT05768997","phase":"PHASE3","title":"High Dose IV Iron Plus ESA in Chemotherapy-induced Anemia","status":"UNKNOWN","sponsor":"Hallym University Medical Center","startDate":"2023-03-01","conditions":"Anemia","enrollment":312}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":29,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["More intensive target"],"phase":"marketed","status":"active","brandName":"High-dose ferric derisomaltose","genericName":"High-dose ferric derisomaltose","companyName":"China-Japan Friendship Hospital","companyId":"china-japan-friendship-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"High-dose ferric derisomaltose delivers iron directly to iron-deficient patients via a stable iron-carbohydrate complex that is absorbed and utilized for hemoglobin synthesis. Used for Iron deficiency anemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}